Editorial comment: Reduction in calcineurin inhibitor exposure and maintenance of effective immunosuppression: Clinical experience with everolimus (Certican)

Transplantation

Volumn 79, Issue 9 SUPPL., 2005, Pages

  Monaco, Anthony P ^a   Morris, Peter J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; CALCINEURIN; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT;

CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; EDITORIAL; GRAFT FAILURE; HUMAN; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LEUKOPENIA; NEPHROTOXICITY; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; DRUG ANTAGONISM; IMMUNOLOGY; TREATMENT OUTCOME;

CALCINEURIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; SIROLIMUS; TREATMENT OUTCOME;

EID: 21244484973     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200505153-00001     Document Type: Editorial

References (1)

1. Mota A, Arias M, Taskinen EI, et al. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 2004; 4: 953.